| Infliximab(n = 17) | Placebo(n = 9) | Test | p Value | Total | |||
| Mean | SD | Range | |||||
| Demographics | |||||||
| Gender (proportion female) | 14/17 | 8/9 | χ2 test | 0.660 | 22/26 | ||
| Age (years) | 48 (12) | 50 (16) | t test | 0.663 | 49 | (14) | 29–77 |
| Vascular assessments | |||||||
| PWV (m/s) | 8.8 (1.4) | 9.4 (2.3) | t test | 0.438 | 9.0 | (1.7) | 6.5–12.7 |
| Mean CIMT (mm) | 0.9 (0.3) | 0.9 (0.3) | t test | 0.709 | 0.9 | (0.3) | 0.4–1.6 |
| CAP (number with each combined grade 0/1/2/3/4) | 9/4/2/1/1 | 7/0/0/2/0 | χ2 test | 0.226 | 16/4/2/3/1 | ||
| RA disease activity | |||||||
| RF-positive (proportion) | 7/16 | 7/8 | χ2 test | 0.040 | 14/24 | ||
| ESR (mm/h) | 39 (26) | 40 (24) | t test | 0.882 | 39 | (24) | 3–88 |
| CRP (mg/l) | 32 (47) | 30 (21) | t test | 0.898 | 32 | (39) | 4–186 |
| Patient global assessment (100 mm) | 68 (15) | 70 (25) | t test | 0.829 | 69 | (18) | 37–100 |
| Tender joint count (out of 28) | 14 (7) | 15 (7) | t test | 0.837 | 14.5 | (6.8) | 3–26 |
| Swollen joint count (out of 28) | 10 (5) | 12 (5) | t test | 0.286 | 10.5 | (5.1) | 3–21 |
| DAS28 | 6.2 (0.9) | 6.4 (0.8) | t test | 0.554 | 6.3 | (0.8) | 5.2–7.9 |
| Cardiovascular risks | |||||||
| Smoking status (non/ex/current), N | 9/5/3 | 5/3/1 | χ2 test | 0.905 | 14/8/4 | ||
| Heart rate (beats/min) | 69 (11) | 72 (11) | t test | 0.570 | 70 | (11) | 47–90 |
| Systolic BP (mm Hg) | 121 (14) | 124 (18) | t test | 0.642 | 122 | (15) | 97–153 |
| Diastolic BP (mm Hg) | 75 (7) | 74 (8) | t test | 0.951 | 74 | (8) | 66–99 |
| BMI (kg/m2) | 26.0 (6.7) | 25.7 (6.7) | t test | 0.921 | 25.8 | (7) | 17–42 |
| Total cholesterol (mmol/l) | 5.1 (1.2) | 4.7 (0.8) | t test | 0.242 | 4.9 | (1.1) | 2.9–7.6 |
| LDL cholesterol (mmol/l) | 3.3 (1.0) | 2.9 (0.7) | t test | 0.369 | |||
| HDL cholesterol (mmol/l) | 1.3 (0.4) | 1.2 (0.3) | t test | 0.568 | 1.3 | (0.4) | 0.8–2.3 |
| Triglycerides (mmol/l) | 1.0 (0.5) | 0.8 (0.3) | t test | 0.207 | 3.2 | (0.9) | 1.3–5.1 |
| HOMA | 12.4 (10.1) | 6.8 (3.1) | t test | 0.214 | 10.7 | (8.9) | 3.1–34.9 |
| Adiponectin | 18773 (7168) | 18523 (6898) | t test | 0.933 | 18686 | (6938) | 7075–36623 |
Data reported as mean (SD) unless otherwise noted.
BMI, body mass index; BP, blood pressure; CAP, carotid artery plaque; CIMT, carotid intimal medial thickness; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; HOMA, insulin resistance measured by log homeostasis model assessment; LDL, low-density lipoprotein; PWV, pulse wave velocity; RA, rheumatoid arthritis; RF, rheumatoid factor.